MOSCOW/LONDON (Sputnik) - Mortality rate after the use of the Pfizer coronavirus vaccine in six European countries is significantly higher than after the AstraZeneca.
The U.S. Food and Drug Administration issued an emergency use authorization for the third COVID-19 vaccine developed by Johnson & Johnson.
Still, how could this happen? Blais never stopped wearing personal protective equipment at work or masking outside her home. She got infected where she least expected it. I had a direct exposure from a close family member, she said.
Blais was hesitant to share her experience because she was concerned about the comments anti-vaxxers may make and that people who are vaccine-hesitant may become even more so. But, doctors say what happened to Blais is proof the vaccine works.
The U.S. Food and Drug Administration issued an emergency use authorization for the third COVID-19 vaccine developed by Johnson & Johnson.
Still, how could this happen? Blais never stopped wearing personal protective equipment at work or masking outside her home. She got infected where she least expected it. I had a direct exposure from a close family member, she said.
Blais was hesitant to share her experience because she was concerned about the comments anti-vaxxers may make and that people who are vaccine-hesitant may become even more so. But, doctors say what happened to Blais is proof the vaccine works.
Coronavirus: Pfizer vaccine 94% effective, confirms mass real-world study
The research involved about 12 lakh people in Israel. File photo: Syringes prepared for the Pfizer-BioNTech coronavirus vaccine. | Hannibal Hanschke/Reuters
A big real-world test of Pfizer and BioNTech’s coronavirus vaccine has shown that the jab is 94% effective. The results of the study, which involved about 12 lakh people in Israel, were published in the
New England Journal of Medicine on Wednesday
.
The results are very close to the vaccine’s phase 3 clinical trials last year, which found that two doses were 95% effective.
The study estimated the vaccine to be 57% effective against the infection two to three weeks after the first dose and 94% effective a week or longer after the second dose. It involved 6 lakh inoculated people and a similarly-sized control group of unvaccinated participants.
The good news came as Ghana became the first country to receive shots under the global Covax scheme, paving the way for poorer nations to catch up with wealthier parts of the world.